Cambrex

Steven M. Klosk has been appointed president and chief executive officer and a member of the board of directors of Cambrex. James A. Mack, president and chief executive officer since 1995 and chairman since 1999, has announced plans to retire. The company will separate the positions of chairman and chief executive officer and John R. Miller, currently lead director, will assume the position of non-executive chairman of the board. Mr. Mack will remain a board member and advisor until his retirement on June 30, 2008.
    
Mr. Klosk joined Cambrex in October 1992 as vice president, administration. He held several positions of increasing responsibility serving as executive vice president, administration, executive vice president and chief operating officer for Cambrex Pharma and BioPharmaceutical Business Unit, and assumed direct responsibility for the BioPharmaceutical Business Unit serving as chief operating officer. In January 2007 he was appointed executive vice president and chief operating officer for the Corporation.  
   
“I have enjoyed my many years with Cambrex and now is the right time to turn the Company over to new leadership. I am confident that with his many years with Cambrex, Steve will ably continue the pattern of growth that is so much a part of the Company,” commented Mr. Mack.
   
“I am excited about the opportunity to lead the Cambrex team as we focus on our growth initiatives in proprietary products and polymeric drug delivery, highly potent compounds, controlled substances and our growing pipeline of new custom development products. In addition, we are well positioned to leverage our recently completed facility near Milan, Italy to support our leading position in generic active pharmaceutical ingredients,” said Mr. Klosk. “I am extremely grateful to Jim for his many years of outstanding service to Cambrex and for his personal mentorship.”